Research programme: recombinant human acid ceramidase - Plexcera Therapeutics

Drug Profile

Research programme: recombinant human acid ceramidase - Plexcera Therapeutics

Alternative Names: Recombinant human acid ceramidase; rhAC; RVT-801

Latest Information Update: 05 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer Enzyvant Sciences; Plexcera Therapeutics
  • Class Ceramidases
  • Mechanism of Action Acid ceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Farber lipogranulomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Farber lipogranulomatosis
  • Discontinued Cystic fibrosis

Most Recent Events

  • 04 Jun 2018 Enzyvant plans to file an IND application for a clinical trial for Farber lipogranulomatosis
  • 16 Oct 2017 Recombinant human acid ceramidase receives Orphan Drug status for Farber lipogranulomatosis in European Union before October 2017
  • 16 Oct 2017 Enzyvant plans a clinical trial for Farber lipogranulomatosis in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top